Learn about clinical trials and research opportunities in Diagnosis/Treatment section
Learn about clinical trials and research opportunities in Diagnosis/Treatment section
CURE OM's 12th "Eyes on a Cure: Patient & Caregiver Symposium"
When: March 31 – April 2, 2023
Where: Tampa, Florida (and Online)
CLICK ON AN OCULAR MELANOMA CONFERENCE BELOW TO SEE THE LIST OF PRESENTATIONS, NAMES OF PRESENTERS, AND VIDEO LINKS.
OM Diagnosis, Genetics, Treatment, and Research:
• KIMMTRAK Approved: Now What? (Dr. Meredith McKean and Dr. Justin Moser; 50 minutes)
• Ocular Melanoma Mets Explained (Dr. Meredith McKean, Dr. Justin Moser, and Dr. Maureen Sanger; 50 minutes)
• Standards of Care in Uveal Melanoma (Dr. Peter Hovland, Dr. David Reichstein, and Dr. Amy Schefler; 55 minutes)
• What Is the INSIGHT Registry? (Dr. Armin Afshar; 35 minutes)
• Your Eye After Treatment (Dr. David Reichstein; 55 minutes)
Mental Health and Self-Advocacy:
Links to videotaped conference presentations on these two topics can be found on EyeMelanoma.org's Patient Empowerment webpage.
Low Vision:
Link to videotaped conference presentation on low-vision tools and techniques can be found on EyeMelanoma.org's Vision-Related Support webpage.
All videotaped presentations from this conference
Video Recordings of Clinical Research Sessions: Part 1
• Primary Ocular Melanoma 101 (Dr. Carol Shield; 51:25 to 1:27:04)
• Post-Primary Treatment (Dr. Sara Lally; 1:27:04 to 1:51:21)
• Surveillance and Adjuvant Therapy (Dr. Rino Seedor; 1:51:21 to 2:10:00)
• Past, Present, and Future of Uveal Melanoma (Dr. Takami Sato; 2:49:00 to 3:19:40)
Video Recordings of Clinical Research Sessions: Part 2
• Treatments for Metastatic Disease: Liver Directed Therapies (Order of presenters: Dr. Rani Anne, Dr. Robert Adamo, and Dr. Carin Gonsalves; 0:00 to 1:08:07)
• Treatments for Metastatic Disease: Immunotherapies (Marlana Orloff; 1:08:07 to 1:34:52)
• Treatments for Metastatic Disease: Molecular Targeted Therapies (Dr. Rino Seedor; 1:34:52 to 1:51:57)
• Basic Science Updates (Dr. Andrew Aplin; 1:51:57 to 2:19:07)
• Closing Remarks (Dr. Sara Selig; 2:19:07 to 2:25:00)
• Current and Emerging Systemic Treatment Choices for Metastatic Uveal Melanoma (Dr. Paul Nathan; 30 minutes)
• Novel Treatments of Uveal Melanoma (Prof. Jonas Nilsson; 20 minutes)
• Liver-Directed Therapies for Metastatic Uveal Melanoma (Dr. David Eschelman; 20 minutes)
• Australian National Uveal Melanoma Treatment Pathway (Dr. John McKenzie; 20 minutes)
• Ocular Prostheses (Ocularist Camille Loyer; 15 minutes)
• A Global Survey on Ruthenium Eye Plaque Practice (Dr. Lotte Fog; 15 minutes)
• Another Option in the Radiotherapy Toolkit: Gantry-Based Proton Therapy (Dr. Amanda Deisher; 15 minutes)
• Proton Therapy for Uveal Melanoma (Dr. Sachin Salvi; 20 minutes)
• Pathology of Uveal Melanoma (Prof. Penny McKelvie; 20 minutes)
• Transretinal Tumour Biopsy Techniques (Prof. Heinrich Heimann; 15 minutes)
• Uveal Melanoma Biopsy at the Time of Plaque Brachytherapy (Dr. Rod O'Day; 15 minutes)
• Genetics and Genomics in Uveal Melanoma (Dr. Peter Johansson; 15 minutes)
• Proteomics in Uveal Melanoma (Prof. Sarah Coupland; 15 minutes)
• Liquid Biopsies in Uveal Melanoma (Dr. Aaron Beasley; 15 minutes)
OM Diagnosis, Genetics, Treatment, and Research:
• Ocular Melanoma Advocacy (Melanoma Research Foundation's Cassie Beisel; 50 minutes)
• Ocular Melanoma Clinical Trials (Dr. Richard Carvajal, Dr. Marlana Orloff, Dr. Sapna Patel, and Dr. Sara Selig; 75 minutes)
• Upcoming Ocular Melanoma Treatments (Dr. Richard Carvajal and Dr. Sara Selig; 35 minutes)
• VISION Registry Update (Dr. Richard Carvajal and Dr. Sara Selig; 60 minutes)
All videotaped presentations from this conference
OM Diagnosis, Genetics, Treatment, and Research:
• How My Patients Made Me a Better Ocular Oncologist (Dr. Bertil Damato; 45 minutes)
• Keynote Presentation: What's New in Uveal Melanoma in 2021 (Dr. Prithvi Mruthyunjaya; 45 minutes)
• Making Drug Development Work For Uncommon Cancers (Dr. Anthony Tolcher; 45 minutes)
• Navigating a Diagnosis of Metastatic Uveal Melanoma (Dr. Adil Daud and Dr. Justin Moser; 50 minutes)
• Treatment of Advanced Uveal Melanoma (Dr. Jose Lutzky; 45 minutes)
• Uveal Melanoma Genetics Explained (Genetic counselor Jaime Jessen and Dr. Basil Williams; 50 minutes)
• What to Expect After Radiation Treatment for Uveal Melanoma: A Patient's Perspective (Dr. Armin Afshar and Dr. Timothy Murray; 50 minutes)
• What's New in Uveal Melanoma — NCCN Guidelines' Prognostic Information and Standards of Care (Dr. David Reichstein, Dr. Amy Schefler, and Dr. Andrew Stacey; 50 minutes)
• Why Should I Join a Registry? About the INSIGHT Ocular Melanoma Patient Registry (Dr. Armin Afshar and Dr. Bertil Damato; 45 minutes)
Mental Health and Self-Advocacy:
Links to videotaped conference presentations on these two topics can be found on EyeMelanoma.org's Patient Empowerment webpage.
Low Vision:
Links to videotaped conference presentations on low-vision tools and techniques can be found on EyeMelanoma.org's Vision-Related Support webpage.
All videotaped presentations from this conference
All the meeting's ocular melanoma presentations can be viewed in the following two parts by anyone after free online registration. (Note: Select "not a healthcare professional" to eliminate pre-test process for continuing education credit.)
Part 1:
One-hour video — OM presentations begin at 11:50 mark in the following order:
• Potential Application of Liquid Biopsies for Uveal Melanoma (Dr. Elin Gray; 6 minutes)
• Uveal Melanoma: Proteomic Biomarkers (Dr. Vinit Mahajan; 5 minutes)
• Molecular-Guided Clinical Trial Design in Uveal Melanoma (Dr. J. William Harbour; 7 minutes)
• Panel Discussion (24 minutes)
Part 2:
Two-hour video — In its first hour, OM presentations begin at 14:20 mark in the following order:
• Targeted Treatment of Uveal Melanoma with Viral-Like Drug Conjugates (Dr. Ivana Kim; 6 minutes)
• Dose Reduction Strategies for Plaque Brachytherapy (Dr. Miguel Materin; 5 minutes)
• Anti-VEGF vs. Intravitreal Steroids for Prevention of Vision Loss Due to Radiation Retinopathy (Dr. Daniel Martin; 8 minutes)
• Panel Discussion (26 minutes)
In its second hour, OM presentations begin at 1:07:10 mark in the following order:
• Drug Toxicities from Cancer Therapies (Dr. Dan Gombos; 7 minutes)
• Machine Learning in Ocular Melanoma Detection (Dr. Mandeep Sagoo; 8 minutes)
• AI-Based Histopathologic Tumor Analysis (Dr. Zelia Correa; 6 minutes)
• Panel Discussion (21 minutes)
• A Perspective on Unmet Needs in Uveal Melanoma (Dr. Carol Shields; 10 minutes)
• Activating a Research Network to Tackle a Yet Uncured Disease: COOG2 (Dr. Thomas Aaberg, Jr.; 7 minutes)
• Panel Discussion (25 minutes)
Overview of Ocular Melanoma:
• Conjunctival Melanoma: Diagnosis to Treatment (Dr. Dan Gombos; 25 minutes)
• OM in Childhood (Dr. Mandeep Sagoo; 10 minutes)
• OM Patient Care: New Zealand and Australia Perspective (Dr. Peter Hadden and Dr. Li-Anne Lim; 45 minutes)
• Primary OM 101 (Dr. Dan Gambos; 40 minutes)
• What is Uveal Melanoma? What is Conjunctival Melanoma? (Dr. Amit Arora and Dr. Mandeep Sagoo; 30 minutes)
OM Diagnosis, Genetics, Treatment, and Research:
• Advantages and Disadvantages of Different Types of Radiotherapy for Uveal Melanoma in the UK (Dr. Rumana Hussain; 20 minutes)
• Adjuvant Therapy (Dr. Marlana Orloff; 30 minutes)
• Clinical Trials: An International Overview (Panel Discussion) (Dr. Marcus Butler, Dr. Richard Carvajal, Dr. John Crown, and Dr. Anthony Joshua; 30 minutes)
• Collaborative Ocular Oncology Group's COOG2 Study (Dr. Prithvi Mruthyunjaya; 15 minutes)
• Current Treatment Options: Liver-Directed Therapy, Immunotherapy, Targeted Therapy, and Looking to the Future, Plus COVID-19 Update (Dr. Marlana Orloff and Dr. Sapna Patel; 50 minutes)
• Genomic Landscape of Uveal Melanoma (Dr. Nicholas Hayward; 50 minutes)
• Liver-Directed Interventional Radiology in the UK (Dr. Sachin Modi and Dr. Brian Stedman; 25 minutes)
• Liver-Directed Interventional Radiology in the US (Dr. Ravi Murthy and Dr. Bruno Odisio; 25 minutes)
• OM Treatment Progress Over the Last Few Decades (Dr. Sapna Patel; 25 minutes)
• Precision (Personalized) Medicine in Choroidal Melanoma (Dr. Tim Crook; 25 minutes)
• Prospective Ocular Melanoma Natural History Study ("OMNI") (Dr. Joseph Sacco; 15 minutes)
• Radiation Oncology (Dr. Clare Phillips; 30 minutes)
• Radiation Side Effects on the Retina, Including Radiation Maculopathy (Dr. Heinrich Heimann; 40 minutes)
• Side Effects of Plaque Brachytherapy Treatment of Ocular Melanoma (Dr. Peter Hovland; 25 minutes)
• Translational Research: Genomic Landscape of UM, Immunotherapy for Metastatic UM, and Liquid Biopsies (Dr. Elin Gray, Dr. Nicholas Hayward, and Dr. Jonas Nilsson; 50 minutes)
• Update on CURE OM's VISION Patient Registry (Dr. Richard Carvajal, OM patient Chad, Dr. Marlana Orloff, and Global Vision Technologies' George Ritacco; 60 minutes)
• Update on Unique Ocular Melanoma Populations (Huntersville in North Carolina and Auburn in Alabama) (Dr. Marlana Orloff; 30 minutes)
Mental Health and Self-Advocacy:
Links to videotaped symposium presentations on these two topics can be found on EyeMelanoma.org's Patient Empowerment webpage.
All videotaped presentations from this symposium
In order to highlight the latest information on all topics, only ocular melanoma conference presentations made during the past two years are listed on this webpage.
New information added to this webpage: November 21, 2022
Links to all external sites re-verified on this webpage: June 15, 2022
Email: Erica@EyeMelanoma.org
This not-for-profit website does not contain any advertisements and does not receive funding/donations of any kind.
Information on this site should not be used as a substitute for professional medical care or advice.
Copyright © 2011–2023. EYEMELANOMA.ORG. All Rights Reserved.
EyeMelanoma.org has been providing current information on ocular melanoma since 2011.
This nonprofit website does not contain any advertisements and does not receive funding/donations of any kind.
Google Analytics is used within this site to determine the number of visitors. Data is anonymous.